<DOC>
	<DOCNO>NCT02335411</DOCNO>
	<brief_summary>This study pembrolizumab advance gastric gastroesophageal junction adenocarcinoma ; pembrolizumab give monotherapy participant previous treatment treatment-naïve ; pembrolizumab also evaluate combination therapy cisplatin 5-Fluorouracil ( 5-FU ) ( Japan ) capecitabine treatment-naïve participant . The primary study hypothesis pembrolizumab provide clinically meaningful overall response rate .</brief_summary>
	<brief_title>A Study Pembrolizumab ( MK-3475 ) Participants With Recurrent Metastatic Gastric Gastroesophageal Junction Adenocarcinoma ( MK-3475-059/KEYNOTE-059 )</brief_title>
	<detailed_description>This study 3 cohort . Cohorts 1 2 run simultaneously ; Cohort 3 start biomarker assay validation complete . In Cohort 1 , participant receive least two prior therapy advance disease receive monotherapy pembrolizumab . In Cohort 2 , participant receive previous therapy disease receive pembrolizumab combination cisplatin 5-FU ( Japan ) capecitabine . In Cohort 3 , participant receive previous therapy program cell death ligand 1 ( PD-L1 ) -positive tumor receive monotherapy pembrolizumab .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Inclusion Criteria Cohort 1 : Received progress least 2 prior chemotherapy regimen advance disease ; prior regimen must include cisplatin fluoropyridine Human epidermal growth factor receptor 2 ( HER2/neu ) negative , , HER2/neu positive , must previously receive treatment trastuzumab Inclusion Criteria Cohort 2 3 : HER2/neu negative Has receive prior systemic anticancer therapy advance carcinoma ( systemic therapy receive neoadjuvant adjuvant set count ) Inclusion Criteria All Participants : Histologically cytologicallyconfirmed recurrent metastatic gastric gastroesophageal junction adenocarcinoma consider incurable local therapy Willing provide tissue PDL1 biomarker analysis newlyobtained and/or archival tissue Measurable disease base Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST 1.1 ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 within 3 day prior first dose study medication Life expectancy &gt; = 3months Female participant childbearing potential negative pregnancy test willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication ( 180 day participant receive cisplatin + 5FU ) Male participant agree use adequate method contraception start first dose 120 day last dose study medication ( 180 day participant receive cisplatin + 5FU ) Adequate organ function Currently participate receive study therapy participate study investigational agent receive study therapy use investigation device within 4 week first dose study medication Active autoimmune disease require systemic treatment past 2 year Immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study medication Weight loss &gt; 10 % 2 month prior first dose study medication Clinical evidence ascites physical exam Prior anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover adverse event due agent administer 4 week earlier Prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover adverse event due previously administer agent Known additional malignancy progress require active treatment except basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Known history , evidence active , noninfectious pneumonitis Active infection require systemic therapy Psychiatric substance abuse disorder would interfere cooperation requirement study Pregnant breastfeeding , expect conceive father child within project duration trial , start screen visit 120 day last dose study medication ( 180 day participant receive cisplatin + 5FU ) Prior therapy antiPD1 , antiPDL1 , antiPDL2 agent Human immunodeficiency virus ( HIV ) Hepatitis B C Received live vaccine within 30 day plan start study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>Gastroesophageal junction cancer</keyword>
	<keyword>PD1</keyword>
	<keyword>PDL1</keyword>
</DOC>